Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Year

Dec 08, 2016

PTC Therapeutics Receives France's 2016 Prix Galien for Translarna™

- Award recognizes scientific innovation of first approved drug for underlying cause of nonsense mutation Duchenne muscular dystrophy -

Nov 18, 2016

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , Nov. 18, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that on November 17, 2016 it approved non-statutory stock options to purchase an aggregate of 33,600 shares of its common stock to eight new employees.

Nov 11, 2016

CHMP Recommends Renewal of Translarna's™ Marketing Authorization for Nonsense Mutation Duchenne Muscular Dystrophy Based on Continued Positive Benefit-Risk Assessment

--PTC to conduct a post-authorization clinical trial --

Nov 02, 2016

PTC Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update

- Record quarter with Translarna™ net sales of $22M; 125% year-over-year growth -
- YTD Translarna net sales of $56M; on track for $65M to $85M full year guidance -
- Successful pricing and reimbursement negotiations concluded in Italy and Romania -
- CHMP opinion regarding Translarna's EMA marketing renewal expected by year-end -
- SMA program advancing with Phase 2 SUNFISH study initiated in Type 2/3 patients -

Oct 20, 2016

Spinal Muscular Atrophy Program Advances into Phase 2 Clinical Studies in SMA Patients with RG7916

- Initiated SUNFISH study to evaluate RG7916 in Type 2/3 SMA patients -
- FIREFISH study in Type I SMA patients expected to begin in the coming months -

Oct 19, 2016

PTC Therapeutics to Host Conference Call to Discuss Third Quarter Financial Results

SOUTH PLAINFIELD, N.J. , Oct. 19, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that the Company will host a webcast conference call to report its third quarter financial results and provide an update on the company's business and outlook on Wednesday, November 2,

Oct 17, 2016

PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) for Nonsense Mutation Duchenne Muscular Dystrophy

SOUTH PLAINFIELD, N.J. , Oct. 17, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) today provided a regulatory update on Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). U.S. regulatory update PTC Therapeutics announced today that at the

Oct 06, 2016

PTC Therapeutics Announces New Analyses that Support the Potential Benefit of Ataluren in Preserving Lung Function in Non-Ambulatory Nonsense Mutation Duchenne Muscular Dystrophy Patients

SOUTH PLAINFIELD, N.J. , Oct. 6, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced new data supporting the potential benefit of ataluren in preserving lung function in non-ambulatory nonsense mutation Duchenne muscular dystrophy patients (nmDMD).

Oct 04, 2016

New Research Validates Translarna's™ (ataluren) Mechanism of Action to Promote Readthrough of Nonsense Mutations and Produce Full-length Functional Protein

- Data published in the Proceedings of National Academy of Sciences (PNAS) -
- Results show ataluren targets the protein production machinery -

Sep 12, 2016

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , Sept. 12, 2016 /PRNewswire/ -- PTC Therapeutics , Inc. ( NASDAQ : PTCT) today announced that on September 8, 2016 it approved non-statutory stock options to purchase an aggregate of 22,900 shares of its common stock to eleven new employees.

Pagination

First page
Previous page
…
Page 34
Page 35
Current page 36
Page 37
Page 38
…
Next page
Last page